menu

CME: Hemophilia Patient Cases: Managing the Challenges of Inhibitors

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Hemophilia Patient Cases: Managing the Challenges of Inhibitors

Hemophilia Patient Cases: Managing the Challenges of Inhibitors
RestartResume
Learn about challenging cases of hemophilia with inhibitors, including identifying risk factors, evaluating treatments, and counseling patients.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hemophilia patients that develop inhibitors to factor replacement therapy are not only at increased risk for morbidity and mortality, they pose substantial challenges for treatment and management paradigms. The treatment of hemophilia patients with inhibitors with bypassing agents can be unpredictable.

    During “Hemophilia Patient Cases: Managing the Challenges of Inhibitors”, members of the interprofessional team caring for patients with hemophilia will be challenged in their application of recent advances in the understanding of the genetic and non-genetic risk factors associated with inhibitor development. They will gain greater insights into the evidence on the safety, efficacy, and outcomes associated with bypassing agents. Optimally, the primary goal of the management of patients with inhibitors is the eradication of the inhibitor, and to this end, the activity will also update participants on new and emerging approaches in prophylaxis and immune induction tolerance induction. It is anticipated that members of the team caring for a patient with hemophilia with inhibitors will gain knowledge and skills to enable them to communicate more efficiently with each other, and with their patient, regarding management options.

  • Fee Information

    There is no fee for this educational activity.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Shannon L. Meeks, MD
    Associate Professor of Pediatrics
    Aflac Cancer and Blood Disorders Center
    Emory University/Children’s Healthcare of Atlanta
    Atlanta, GA

    Faculty’s disclosure:

    Dr. Shannon L. Meeks receives consulting fees from Bayer, Bioverativ, CSL Behring, Genentech, Grifols, HEMA Biologics, Novo Nordisk, and Shire.  

    Reviewers/Planners/Authors:

    • Christa Dardaganian has nothing to disclose
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.

    Planners and Managers

    The PIM planners and managers have nothing to disclose

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify patients at risk for development of inhibitors towards factor replacement therapy.
    • Evaluate the mechanisms, safety, efficacy, complications, and outcomes associated with bypassing agents, immune tolerance induction strategies, including the assessment of the advantage and clinical evidence on the use of EHL factors for ITI, and other novel approaches to treat and manage hemophilia patients with inhibitors.
    • Demonstrate increased ability to better counsel patients and the members of the care team regarding risk factors for inhibitors formation and management options through a case vignette.
  • Target Audience

    This activity is designed to meet the educational needs of hematologists and hematology nurses.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and Postgraduate Institute for Medicine (PIM). TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Joint Accreditation Statement 

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. 

    Interprofessional Continuing Education 


    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by independent educational grants from Bioverativ, a Sanofi Company and Shire.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.